Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
The Latest on: Antibody Drug Conjugates
[google_news title=”” keyword=”Antibody Drug Conjugates” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antibody Drug Conjugates
- Pfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugateson March 2, 2024 at 11:00 am
Antibody-drug conjugates, a relatively new class of therapy that is improving cancer treatment, are likely to be a boon for the bottom line of companies marketing and developing them. In 2028, revenue ...
- ADC Market Will Remain Hot in Oncology, Reaching $30B by 2028: Reporton March 1, 2024 at 6:16 am
Antibody-drug conjugates are a breakthrough in targeted cancer therapy and will continue to attract big pharma investment over the next few years, finds a new report from market intelligence firm ...
- Pfizer Focuses on Four Main Cancer Types, Eyes Eight Blockbusters by 2030on March 1, 2024 at 3:52 am
At Thursday’s Oncology Innovation Day, Pfizer laid out its business strategy which includes building up its biologics business, specifically antibody-drug conjugates and bispecific antibodies.
- Bioconjugates Meet and Promise to Exceed Expectationson February 29, 2024 at 4:00 pm
One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...
- Antibody-Drug Conjugates Challenges and Trendson February 29, 2024 at 4:00 pm
As noted in MaryAnn Labant’s article on p. 28, antibody-drug conjugates (ADCs) represent a promising next-generation technology for targeting many diseases. However, as in any evolving technology, ...
- Pfizer fleshes out oncology strategy, targeting 8 blockbuster cancer drugs by 2030on February 29, 2024 at 1:42 pm
In what CEO Albert Bourla called an update to a top priority at Pfizer, the company on Thursday systemically laid out its new oncology strategy following the $43 billion acquisition of antibody-dru | ...
- Pfizer revamps oncology R&D strategyon February 29, 2024 at 10:03 am
After investing heavily in COVID-19 over the last few years, Pfizer is pivoting to zoom in on cancer, with a laser focus on next-gen antibody-drug conjugates (ADCs), small molecules and bispecific ...
- In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trialson February 29, 2024 at 2:31 am
Abingworth will offer Gilead up to $210 million to support select clinical studies of the California pharma’s antibody-drug conjugate Trodelvy, with a focus on non-small cell lung cancer, the life ...
- What to Expect From an Antibody-Drug Conjugate for HR+/HER2- Metastatic Breast Canceron February 26, 2024 at 4:00 pm
An antibody-drug conjugate may be prescribed when other breast cancer treatments don’t work. Learn what to expect when starting this targeted therapy.
- These Drug Companies Are Going Nuclear to Fight Canceron February 20, 2024 at 3:30 am
Big pharma’s investments in nuclear medicine highlight how cancer treatment is shifting to targeted approaches.
via Bing News